CYTOF
Altamira Therapeutics Ltd.
$0.06
+0.00 (+3.23%)
At close · Jul 2
Market Cap
$365,790
Shares
4,662,080
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.06
Open$0.06
Day$0.06–0.06
52W$0.05–0.15
Avg vol 30d4K
Short int17K · 0.4% float · 3.3d
Short vol89%
DataJan 2020–Jul 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
Technical · trend & momentum
Strong Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−24% below
−
Price vs 50-day avg
−23% below
◦
RSI (14)
46 · neutral
−
MACD trend
negative
−
52-week position
14% · near low
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $0 › 200d $0 — 200d above 50d
◦
Institutional flow
No 13F holder data
◦
Insider flow
No net insider activity over 90 days
◦
Short interest
0.36% of float · ▬ 0.0% MoM · 3.3 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
No 13F holder history
Fundamentals
Limited data
Not enough data for a confident read.
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−24% below
Bearish
Price vs 50-day avg
−23% below
Bearish
RSI (14)
46 · neutral
Neutral
MACD trend
negative
Bearish
52-week position
14% · near low
Bearish
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.36% of float · ▬ 0.0% MoM · 3.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
52-wk low $0
Now $0 · 14%
52-wk high $0
vs 200-day avg -24%
vs 50-day avg -23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CYTOF
this stock
Altamira Therapeutics Ltd.
|
$365,790 | -30.4% | — | — | 0.4% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CYTOF | -46.7% | -16.9% | -36.0% | -34.0% | -30.4% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -48.1% | -15.6% | -44.0% | -33.8% | -39.7% |